Eric T.

Moffitt Cancer Center is a leading nonprofit cancer center in Tampa, Florida focused on multidisciplinary cancer treatment and translational research, with specialized programs in cellular therapies such as CAR‑T and TIL.

• Led program team operations for CAR‑T and TIL oncology programs, coordinating cross‑functional project activities and timelines.
• Consolidated and communicated project status, budgets and timelines to senior stakeholders (PIs, CEO) to enable timely decision making.
• Developed and facilitated executive briefings and stakeholder meetings with PIs, the CEO, and philanthropic funders to align priorities and funding commitments.
• Managed program governance and escalation pathways to remove blockers and keep clinical/translational activities on schedule.
• Owned reporting to key philanthropic funders, ensuring transparent program metrics, milestone tracking and budget stewardship.

• Established a cohesive PM framework at VLP THERAPEUTICS LLC to ensure project alignment and transparency.
• Established procurement process and financial tracking system
• Led core teams towards program objectives and milestones to drive successful project outcomes.
• Managed contractual negotiations, POs, and invoice processing with vendors to optimize project budgeting and resource allocation.
• contract role with end date in 2Q25

• Provided ad hoc guidance to investors and biotech using 30 years of project management experience in drug development.
• Leveraged leadership skills to support clients in achieving their short-/long-term goals.
• Collaborated remotely with clients in the Washington DC-Baltimore Area to deliver tailored solutions.
• Helped JCommerce (Washinton, DC) organize and expedite warehouse operations (Feb 2024-July 2024)

• Led the Product Development Team (PDT) at Corbus Pharmaceuticals, ensuring seamless communication among team members.
• Provided timely and accurate progress reports to Senior Management, facilitating informed decision-making.
• Collaborated with vendors and Finance to ensure precise budgeting and forecasting for R&D projects.
• Established new best practices for project management operations as the lead for the PMO.
• Laid off as part of December 2023 downsizing (approximately 10% workforce)

• Helped lead integration of Alexion into AstraZeneca as the AZ Rare Disease unit, driving strategy development and securing governance approvals.
• Managed cross-functional drug development teams for key milestones on projects like danicopan and vemircopan.
• Achieved successful development, regulatory, and commercial milestones, contributing to the growth of the rare disease unit at AstraZeneca.
• Left as in September 2023 as specific programs were being shut down, pending downsizing

• Led cross-functional drug development teams to achieve key development, regulatory and commercial milestones
• Accomplishments of note are 1) 2022 approval of both Imfinzi + tremelimumab in 1st line HCC; and 2) Imfinzi in 1st line BTC
• Drove strategy development and led new opportunities through governance approvals
• Championed best-practices, drove PM efficiency through leadership/influence of global team members and staff
• Left in Octobers 2022 to join the AZ Rare Disease Unit, Alexion

• Managed program/project team(s) for Partner or Development Company development programs
• Delivered overall program/project timelines and budget, including managing service providers/subcontractors
• Assisted in the development and provision of training and related forums, including PM staff
• Advised senior management staff on project-related issues
• Left after temp assignment completed

• Provided PM and Operations Leadership for R&D drug development programs according to the needs of the organization; oversaw international programs in US, EU, and Israel
• Directly co-led the development of the serine protease inhibitor (upamostat) for oncology and IBS, RHB-204 for NTM infection (bronchiectasis) and RHB-104 for MAP infection diagnostic
• Contract negotiation with vendors, CROs and academic collaborators
• Oversaw basic research at academic centers, institutes, and contract research organizations
• Left when company no longer had funds to support position

• Assisted managing directors and CEO in day-to-day analysis of investment opportunities
• Left after end of contract

• Acted as matrix leader directly supervising experienced drug Project Managers and managing a portfolio governance committee overseeing projects from discovery to lifecycle management
• Acted as member of the department leadership team, setting policy and providing procedural oversight
• Department and position dissolved in late 2016 as part of R&D reorganization

CSL is a global biotechnology company that develops biotherapies and influenza vaccines to treat life‑threatening conditions.

• Supervised a portfolio of ~5 program/project leaders across the recombinant coagulation portfolio and grew project management capability through formal and informal development.
• Acted as program/portfolio representative at Project Governance Committees to align strategy, risk and resource allocation.
• Served as hands‑on PM for specific teams (e.g., device development) when needed to drive technical delivery.
• Led preparation and defense of major capital improvement requests to secure funding for site and program investments.
• Oversaw landmark regulatory submissions for the company’s first recombinant BLAs (Afstyla and Idevio), coordinating cross‑functional teams through filing and approval activities.

Daiichi Sankyo is a global pharmaceutical company focused on creating life‑changing medicines, with a major emphasis on oncology R&D and development of antibody‑drug conjugates and targeted therapies.

• Led multiple global oncology programs across US, EU, Asia and Japan, serving as the primary project lead for cross‑regional clinical development.
• Instituted Daiichi Sankyo’s first fully global oncology Phase 2 study (US/EU/Asia/Japan), establishing processes for multinational execution.
• Designed and launched an Oncology clinical development training program to upskill clinical teams and standardize global practices.
• Mentored and developed junior staff and project managers, increasing organizational bench strength in oncology program management.
• Coordinated cross‑functional stakeholders (clinical, regulatory, CMC, biostatistics) to maintain program timelines and scientific rigor.

Merck (Merck & Co., Inc.) is a multinational pharmaceutical company that follows the science to develop medicines, vaccines and healthcare solutions across multiple therapeutic areas.

• Served as Therapeutic Area Lead (Diabetes & Obesity) for project management, overseeing strategy and delivery across D&O programs.
• Progressed through roles from Project Manager to Associate Director and TA Lead, managing full project lifecycles and governance.
• Managed and mentored junior project managers, increasing team capability and consistent execution across programs.
• Oversaw ~25 projects across ~15 unique targets, providing portfolio oversight, resource prioritization and risk mitigation.
• Coordinated cross‑functional teams to align clinical, regulatory and commercial inputs for program advancement.

Bayer is a global life sciences company active in healthcare and nutrition, driving innovation in pharmaceuticals, consumer health and crop science to address major global challenges.

• Project manager for a gene‑to‑screen alliance with Millennium Pharmaceuticals focused on oncology discovery and translation.
• Led discovery efforts within the Protein Biosciences group, setting scientific priorities and delivering target validation outputs.
• Managed and developed direct reports and coached ~15 indirect reports, fostering scientific growth and performance.
• Coordinated cross‑disciplinary discovery activities (assay development, screening, hit triage) to advance programs toward lead optimization.
• Contributed to alliance management and collaboration governance to ensure milestone achievement and IP alignment.

The National Cancer Institute (NCI) is the U.S. government’s principal agency for cancer research, providing science‑based information and supporting cancer research and discovery.

• Led multidisciplinary research projects in support of small‑molecule drug discovery for oncology.
• Established and executed high‑throughput screening campaigns of the NCI natural compound library to identify novel bioactive leads.
• Designed and implemented assays and hit‑triage workflows to progress screening hits into follow‑up studies.
• Participated in cross‑functional collaborations to translate screening discoveries toward target validation and lead optimization.
• Supervised and guided development of direct reports, building team capabilities in assay execution and data analysis.

GSK (GlaxoSmithKline) is a global healthcare company researching, developing and manufacturing pharmaceuticals, vaccines and consumer healthcare products.

• Investigated structure–activity relationships (SAR) of HIV‑1 protease inhibitors to inform medicinal chemistry optimization.
• Studied the biology and potential role of the Human Endogenous Retrovirus K (HERV‑K) in retroviral research.
• Developed a novel E. coli expression and screening system to enable functional assays and accelerate lead identification.
• Designed and executed experiments that connected biochemical insights to downstream drug discovery decisions.
• Collaborated across molecular genetics and chemistry teams to translate basic findings into screening strategies and candidate progression.